Oxford-AstraZeneca Covid vaccine shows an average 70% effectiveness in preventing the virus
- AstraZeneca said its vaccine, developed in collaboration with the University of Oxford, was assessed over two different dosing regimens.
- One showed an effectiveness of 90% when trial participants received a half dose, followed by a full dose at least one month apart.
- The other dosing regimen showed 62% efficacy when given as two full doses at least one month apart.
- Pascal Soriot, CEO of AstraZeneca, said the development marked an "important milestone" in the fight against the global health crisis.
LONDON — British pharmaceutical giant AstraZeneca said Monday an interim analysis of clinical trials showed its coronavirus vaccine has an average efficacy of 70% in protecting against the virus.
It comes after a string of encouraging vaccine results in recent weeks, following late-stage trial readouts from Pfizer-BioNTech and Moderna.
Pfizer and Moderna reported preliminary results showing that their respective Covid vaccines were around 95% effective.
It is hoped a Covid vaccine could help to bring an end to the coronavirus pandemic that has claimed more than 1.3 million lives worldwide.
The AstraZeneca vaccine, developed in collaboration with the University of Oxford, was assessed over two different dosing regimens.
One dosing regimen showed an effectiveness of 90% when trial participants received a half dose, followed by a full dose at least one month apart. The other showed 62% efficacy when given as two full doses at least one month apart.
The combined analysis from both dosing regimens found average vaccine effectiveness of 70%. No hospitalizations or severe cases of the disease were reported in participants receiving the vaccine.
"These findings show that we have an effective vaccine that will save many lives," professor Andrew Pollard, chief investigator of the Oxford Vaccine Trial, said in a statement.
"Excitingly, we've found that one of our dosing regimens may be around 90% effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply."
A total of 131 Covid-19 cases were assessed in the interim analysis.
An 'important milestone'
More than 23,000 volunteers took part in the trials, conducted in the U.K. and Brazil, with more data to be collected from around the world in coming weeks.
AstraZeneca said additional analysis of the vaccine data could alter the results regarding its average efficacy, and help to establish the duration of the protection.
Pascal Soriot, CEO of AstraZeneca, said the development marked an "important milestone" in the fight against the global health crisis.
"This vaccine's efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency," Soriot said.
"Furthermore, the vaccine's simple supply chain and our no-profit pledge and commitment to broad, equitable and timely access means it will be affordable and globally available, supplying hundreds of millions of doses on approval."
Shares of the company slipped 1.9% in premarket U.S. trading Monday.
AstraZeneca said it would immediately prepare regulatory submission of the data to health authorities around the world that have a framework in place for conditional or early approval.
Huge challenges remain before a vaccine can be rolled out, however. The global battle to secure prospective supplies has raised alarm about equitable access, while questions remain over the logistics of mass production, distribution and cost.
"I think there's also one very important advantage of the AstraZeneca-Oxford vaccine, the ease to use it at refrigerator temperature I think is a very important element of our vaccine so that also, patients and people in low-income countries and middle-income countries can benefit," Ruud Dobber, executive vice president of AstraZeneca's biopharmaceuticals business unit, told CNBC's "Squawk Box" on Monday.
"So, all in all, I think a very exciting day and let's hope that the next steps will go well."
AstraZeneca says its vaccine can be stored, transported and handled at normal refrigerated conditions (36-46 degrees Fahrenheit) for at least six months and administered within existing health-care settings.
It says it is making "rapid progress" in terms of manufacturing with a capacity to produce up to 3 billion doses of the vaccine next year, pending regulatory approval. The company has pledged to distribute the vaccine at no profit "for the duration of the pandemic."
Comparatively, Moderna has said its vaccine candidate remains stable at the temperature of a standard home refrigerator for up to 30 days. It can also be stored for up to six months at negative 4 degrees Fahrenheit.
In August, the U.S. biotechnology firm said it was charging $32 to $37 per dose for its vaccine for some customers.
Pfizer and BioNTech's vaccine requires a storage temperature of minus 94 degrees Fahrenheit and special storage equipment and transportation. This could make it difficult for some countries to distribute.
Pfizer is reportedly charging $20 per dose for its vaccine.